Labeler
Genentech, Inc. NDC Codes
Genentech, Inc. lists 81 finished drug products in the FDA NDC Directory under NDC labeler codes 0004, 50242.
Overview
Each product below links to its own NDC page with package NDCs in 10- and 11-digit form.
- Drugs
- Hemlibra, Xofluza, Actemra, CellCept, TNKase, Rozlytrek, Tamiflu, Lunsumio Velo, Evrysdi, Itovebi, Xolair, Columvi, Lunsumio, Phesgo, Polivy
- Active ingredients
- Hyaluronidase (Human recombinant), Emicizumab, Baloxavir marboxil, Tocilizumab, Mosunetuzumab, Omalizumab, Trastuzumab, Rituximab, Atezolizumab, Entrectinib, Ranibizumab, Pertuzumab
- NDC labeler codes
- 0004, 50242
- Strengths
- Baloxavir marboxil 40 mg/1; Hyaluronidase (Human recombinant) 30000 U/15mL; Tocilizumab 162 mg/.9mL; Rituximab 120 mg/mL; Hyaluronidase (Human recombinant) 2000 U/mL; Trastuzumab emtansine 20 mg/mL; Rituximab 10 mg/mL; Mosunetuzumab 5 mg/.5mL; Mosunetuzumab 45 mg/mL; Baloxavir marboxil 30 mg/1; Risdiplam 5 mg/1; Inavolisib 9 mg/1; Inavolisib 3 mg/1; Ocrelizumab 920 mg/23mL; Hyaluronidase (Human recombinant) 23000 U/23mL; Atezolizumab 1875 mg/15mL; Crovalimab 340 mg/2mL; Emicizumab 12 mg/.4mL; Entrectinib 50 mg/201; Omalizumab 300 mg/2mL
- Dosage forms
- Injection, Solution, Capsule, Tablet, Film coated, Injection, Powder, Lyophilized, For solution, Kit, Injection, Solution, Concentrate, Injection, Concentrate, Granule, For suspension, Tablet, Coated, Powder, For suspension, Tablet, Pellet, Solution, Concentrate, Powder, For solution, Granule, For solution, Solution
- Routes
- Oral, Subcutaneous, Intravenous, Intravitreal, Respiratory (Inhalation)
- Drug classes (FDA established)
- CD20-directed Cytolytic Antibody, Endoglycosidase, HER2/neu Receptor Antagonist, Kinase Inhibitor, Polymerase Acidic Endonuclease Inhibitor, Vascular Endothelial Growth Factor Inhibitor, Interleukin-6 Receptor Antagonist, Anti-IgE, Antimetabolite Immunosuppressant, Programmed Death Receptor-1 Blocking Antibody, Neuraminidase Inhibitor, Survival of Motor Neuron 2 Splicing Modifier, Bispecific CD20-directed CD3 T Cell Engager, Pyridone, Complement C5 Inhibitor, Hedgehog Pathway Inhibitor, Recombinant Human Deoxyribonuclease 1
- HCPCS / J-code
- J2777 — Injection, faricimab-svoa, 0.1 mg, J2778 — Injection, ranibizumab, 0.1 mg, J9022 — Injection, atezolizumab, 10 mg, J9355 — Injection, trastuzumab, excludes biosimilar, 10 mg, J9035 — Injection, bevacizumab, 10 mg, J9312 — Injection, rituximab, 10 mg
- Package NDCs
- 122
NDC codes
Newest listings first. Each row links to the product’s NDC page.
| Product | Strength | Form · route | Product NDC | Package NDCs (11-digit) | HCPCS |
|---|---|---|---|---|---|
| Tecentriqatezolizumab | Atezolizumab 1200 mg/20mL | Injection, SolutionIntravenous | 50242-917 | 50242-0917-0150242-0917-86 | J9022 |
| Alecensaalectinib hydrochloride | Alectinib hydrochloride 150 mg/1 | CapsuleOral | 50242-130 | 50242-0130-0150242-0130-86 | — |
| Cotelliccobimetinib | Cobimetinib fumarate 20 mg/1 | Tablet, Film coatedOral | 50242-717 | 50242-0717-01 | — |
| Gazyvaobinutuzumab | Obinutuzumab 1000 mg/40mL | Injection, Solution, ConcentrateIntravenous | 50242-070 | 50242-0070-0150242-0070-86 | — |
| Actemratocilizumab | Tocilizumab 162 mg/.9mL | Injection, SolutionSubcutaneous | 50242-138 | 50242-0138-0150242-0138-86 | — |
| Kadcylaado-trastuzumab emtansine | Trastuzumab emtansine 20 mg/mL | Injection, Powder, Lyophilized, For solutionIntravenous | 50242-087 | 50242-0087-01 | — |
| Kadcylaado-trastuzumab emtansine | Trastuzumab emtansine 20 mg/mL | Injection, Powder, Lyophilized, For solutionIntravenous | 50242-088 | 50242-0088-01 | — |
| Lucentisranibizumab | Ranibizumab 6 mg/mL | Injection, SolutionIntravitreal | 50242-082 | 50242-0082-0350242-0082-88 | J2778 |
| Perjetapertuzumab | Pertuzumab 30 mg/mL | Injection, Solution, ConcentrateIntravenous | 50242-145 | 50242-0145-01 | — |
| Erivedgevismodegib | Vismodegib 150 mg/1 | CapsuleOral | 50242-140 | 50242-0140-0150242-0140-86 | — |
| Zelborafvemurafenib | Vemurafenib 240 mg/1 | Tablet, Film coatedOral | 50242-090 | 50242-0090-02 | — |
| Tamifluoseltamivir phosphate | Oseltamivir phosphate 6 mg/mL | Powder, For suspensionOral | 0004-0822 | 00004-0822-05 | — |
| Actemratocilizumab | Tocilizumab 80 mg/4mL | Injection, Solution, ConcentrateIntravenous | 50242-135 | 50242-0135-01 | — |
| Actemratocilizumab | Tocilizumab 200 mg/10mL | Injection, Solution, ConcentrateIntravenous | 50242-136 | 50242-0136-01 | — |
| Actemratocilizumab | Tocilizumab 400 mg/20mL | Injection, Solution, ConcentrateIntravenous | 50242-137 | 50242-0137-01 | — |
| Lucentisranibizumab | Ranibizumab 10 mg/mL | Injection, SolutionIntravitreal | 50242-080 | 50242-0080-0350242-0080-88 | J2778 |
| Avastinbevacizumab | Bevacizumab 100 mg/4mL | Injection, SolutionIntravenous | 50242-060 | 50242-0060-01 | J9035 |
| Avastinbevacizumab | Bevacizumab 400 mg/16mL | Injection, SolutionIntravenous | 50242-061 | 50242-0061-01 | J9035 |
| Xolairomalizumab | Omalizumab 150 mg/1.2mL | Injection, SolutionSubcutaneous | 50242-040 | 50242-0040-6250242-0040-86 | — |
| Cathflo Activasealteplase | Alteplase 2.2 mg/2mL | Injection, Powder, Lyophilized, For solutionIntravenous | 50242-041 | 50242-0041-1050242-0041-64 | — |
| Tamifluoseltamivir phosphate | Oseltamivir phosphate 75 mg/1 | CapsuleOral | 0004-0800 | 00004-0800-0700004-0800-85 | — |
| Tamifluoseltamivir phosphate | Oseltamivir phosphate 30 mg/1 | CapsuleOral | 0004-0802 | 00004-0802-85 | — |
| CellCeptmycophenolate mofetil | Mycophenolate mofetil 200 mg/mL | Powder, For suspensionOral | 0004-0261 | 00004-0261-29 | — |
| CellCeptmycophenolate mofetil hydrochloride | Mycophenolate mofetil hydrochloride 500 mg/20mL | Injection, Powder, Lyophilized, For solutionIntravenous | 0004-0298 | 00004-0298-09 | — |
| Rituxanrituximab | Rituximab 10 mg/mL | Injection, SolutionIntravenous | 50242-051 | 50242-0051-21 | J9312 |
| Rituxanrituximab | Rituximab 10 mg/mL | Injection, SolutionIntravenous | 50242-053 | 50242-0053-06 | J9312 |
| CellCeptmycophenolate mofetil | Mycophenolate mofetil 500 mg/1 | Tablet, Film coatedOral | 0004-0260 | 00004-0260-0100004-0260-43 | — |
| CellCeptmycophenolate mofetil | Mycophenolate mofetil 250 mg/1 | CapsuleOral | 0004-0259 | 00004-0259-0100004-0259-43 | — |
| Pulmozymedornase alfa | Dornase alfa 1 mg/mL | SolutionRespiratory (Inhalation) | 50242-100 | 50242-0100-40 | — |
| Activasealteplase | — | Kit | 50242-044 | 50242-0044-13 | — |
| Activasealteplase | — | Kit | 50242-085 | 50242-0085-27 | — |
Genentech, Inc.: common questions
- What is Genentech, Inc.'s NDC labeler code?
- 0004, 50242. The labeler code is the first segment of each NDC. About labeler codes.
- Is there a J-code for Genentech, Inc.?
- Med-Code's HCPCS directory matches J2777, J2778, J9022, J9355, J9035, J9312 to these products. NDC vs J-code.
- Which NDC goes on a claim?
- The package NDC of what was given, in 11-digit form. How to convert a 10-digit NDC.